探究复方异丙托溴铵加布地奈德吸入治疗慢阻肺临床效果分析

殷学明

[摘要] 目的 探究復方异丙托溴铵与布地奈德共同使用通过雾化吸入治疗应用于慢阻肺治疗的临床效果。方法 方便选取2017年8月—2018年8月时间段至该院就诊的45例慢阻肺患者作为该次研究的研究对象。以计算机软件分组将其分为单一组（22例，单一布地奈德吸入治疗）和联合组（23例，复方异丙托溴铵联合布地奈德吸入治疗），对比两组肺功能以及血气分析指标的变化。结果 治疗前，两组患者的肺功能指标以及血气分析指标均差异无统计学意义（t=0.886、0.317，P=0.190、0.376）。治疗后，联合组FEV1（2.04±0.58）L、FVC/FEV1（58.62±8.41）%明显高于单一组（1.45±0.47）L、（50.28±8.67）%（t=3.739、3.276，P=0.000、0.001）。治疗前，两组血气分析指标均差异无统计学意义（t=0.180、0.345，P=0.429、0.366）。联合组血PaCO2（7.58±0.55）kPa、PaO2（11.02±1.74）kPa明显优于单一组（8.04±0.87）kPa、（9.64±2.39）kPa（t=2.130、2.222，P=0.019、0.016）。结论 复方异丙托溴铵联合布地奈德吸入应用于慢阻肺治疗的优势更明显，可明显改善患者肺功能，有利于血气变化，提高临床治疗效果值得临床推广。

[关键词] 复方异丙托溴铵;布地奈德;雾化吸入治疗;慢阻肺;肺功能;血气分析

[中图分类号] R563.8;R563.9          [文献标识码] A          [文章编号] 1674-0742（2020）07（c）-0104-03

[Abstract] Objective To explore the clinical effect of compound ipratropium bromide and budesonide used in the treatment of COPD by nebulized inhalation therapy. Methods Forty-five patients with COPD who visited the hospital from August 2017 to August 2018 were convenient selected as the subjects of this study. Computer software was used to divide it into a single group （22 cases， single budesonide inhalation therapy） and a combined group （23 cases， compound ipratropium bromide combined with budesonide inhalation therapy）， comparing the lung function and blood gas analysis changes in indicators of the two groups on two groups. Results Before treatment， the lung function indexes and blood gas analysis indexes of the two groups were not statistically significantly different（t=0.886， 0.317， P=0.190， 0.376）. After treatment， the combined group FEV1 （2.04±0.58） L， FVC/FEV1 （58.62±8.41）% was significantly higher than the single group （1.45±0.47） L， （50.28±8.67）% （t=3.739， 3.276， P=0.000， 0.001）. Before treatment， there was no statistically significant difference in blood gas analysis indexes between the two groups （t=0.180， 0.345， P=0.429， 0.366）. The blood PaCO2（7.58±0.55） kPa and PaO2 （11.02±1.74） kPa of the combined group were significantly better than the single group （8.04±0.87） kPa and （9.64±2.39） kPa （t=2.130， 2.222， P=0.019，0.016）. Conclusion Compound ipratropium bromide combined with budesonide inhalation has more obvious advantages in the treatment of COPD. It can significantly improve the patient's lung function， is conducive to blood gas changes， and it is worth clinical promotion to improve the clinical treatment effect.

[Key words] Compound ipratropium bromide; Budesonide; Nebulized inhalation therapy; COPD; Lung function; Blood gas analysis